Risk factor
Weak & very vulnerable to price shocks
Profitability factor
Strong margins and returns
About
Chengdu Easton Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the full spectrum of drug development, encompassing research, development, production, and market distribution of medicinal products. The company offers finished medications tailored for various medical disciplines, including pain management (anesthetics/analgesics), cardiovascular health, oncology, and pediatrics. Beyond ready-to-use drugs, it also manufactures active pharmaceutical ingredients (APIs) for a broader range of therapeutic areas, such as cancer treatment, heart conditions, pain relief, anti-inflammatory uses, gastrointestinal issues, antiemetics, neurological and psychiatric disorders, and urinary system ailments. Established in 2009, the firm is headquartered in Chengdu, China.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is fairly valued on P/E, overvalued on EV/E
Target Price
The average target price of 688513.SS is 62.0 and suggests 34.2% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to